Continuous vs. Bolus Administration of NSAIDs After Laparoscopic Surgery for Multimodal Analgesia: Pilot Randomized Controlled Trial

What this Trial Is About

Researchers are investigating the use of continuous infusion versus bolus injection of ibuprofen, a common non-steroidal anti-inflammatory drug (NSAID), for pain management after elective laparoscopic surgery. The study focuses on improving postoperative pain control while reducing opioid use, following the Enhanced Recovery After Surgery (ERAS) guidelines. This Phase 4 trial aims to provide evidence on the effectiveness and safety of continuous ibuprofen infusion, which has not been extensively studied compared to other NSAIDs like paracetamol and ketoprofen. Participants will receive either an experimental continuous infusion or a bolus injection of ibuprofen during their postoperative care. In the continuous infusion group, patients receive an initial bolus dose of 400 mg ibuprofen intravenously, followed by a continuous infusion of ibuprofen over the first two days with doses adjusted by ideal body weight. The bolus injection group also starts with a 400 mg intravenous bolus, then receives three 800 mg bolus injections every eight hours on the first and second days. Placebo infusions or injections are given to maintain blinding between groups. During the study, participants will be monitored for opioid consumption up to 28 days after surgery, which is the primary outcome. Pain intensity will be assessed from admission to the intensive care unit until 48 hours postoperatively. Safety assessments include evaluating liver and kidney function, allergy history, and other health conditions relevant to NSAID use. This randomized, triple-blind trial involves regular intravenous treatments and close observation to understand the benefits and risks of continuous ibuprofen infusion compared to bolus dosing after laparoscopic surgery.

Continuous vs. Bolus Administration of NSAIDs After Laparoscopic Surgery for Multimodal Analgesia